One of the reasons given by Mr Drona for stopping the Phiii early was
"Analysis of these data may lead to a more rapid path to regulatory filing."
And there is clearly great discussion in the US and with the FDA about new trial designs to get new hiv drugs to market more easily
http://www.thebodypro.com/content/art55737.html?getPage=2#experienced
But now, without getting confirmation from the FDA on the path to market, Mr Drona says
"the time and capital required to secure regulatory approval for ATC in key markets may be too large"
So, Mr Drona says
"there is a risk that they (EGMs) may commit the remaining cash in Avexa to the ongoing development of ATC. Given the exhaustive process that has been undertaken to date, it is the Boards view that this would be an extremely poor use of shareholders funds with a very low chance of a successful outcome"
So even though Mr Drona has no confirmation from the FDA for the path to market for ATC, he considers the unknown path too expensive and with a low chance of success, despite that being Mr Drona's own strategy until 3 wks ago on May 10?????????????????????????????????????????????????
Then Mr Drona arranges for a strategic review by his fellow board member's own company!!! hardly an independent review to confirm your decision Mr Drona...
DRONA MUST GO
Add to My Watchlist
What is My Watchlist?